Four moves the government has announced since the end of September:
- The National Institutes of Health is investing $70 million to bring more at-home COVID-19 tests to market. The NIH’s Independent Test Assessment Program plans to establish an accelerated pathway for the FDA to find test manufacturers that can make their tests at a significant scale.
- HHS has invested more than half a billion dollars to boost manufacturing of supplies needed to increase domestic COVID-19 testing. The agency awarded more than $562 million to a dozen U.S. companies to support domestic manufacturing of supplies such as pipette tips, protective packaging, swabs and reagents used in COVID-19 testing.
- The White House said it plans to quadruple the supply of rapid, at-home COVID-19 tests in the U.S. by December. The FDA’s authorization of a rapid test made by San Diego-based Acon Laboratories is expected to double rapid at-home testing capacity. The White House also announced an additional $1 billion investment in rapid testing, building on a previously announced $2 billion investment.
- The U.S. Defense Department and HHS awarded four contracts totaling $647 million to test manufacturers for a total of 60 million over-the-counter test kits.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
